Browsing Tag
thyroid eye disease
6 posts
Amgen (AMGN) stock in focus as subcutaneous TEPEZZA Phase 3 data strengthens thyroid eye disease franchise
Amgen’s Phase 3 subcutaneous TEPEZZA win could reshape thyroid eye disease treatment and competition. Read what it means for AMGN now.
VYNE Therapeutics and Yarrow Bioscience merger signals strategic reset toward autoimmune thyroid therapeutics
Find out how VYNE Therapeutics’ merger with Yarrow Bioscience resets its strategy around a $200M-backed autoimmune thyroid disease pipeline.
Viridian Therapeutics reports 70% durability at one year in Phase 3 THRIVE trial for veligrotug in thyroid eye disease
Viridian's veligrotug maintained a 70% response at 52 weeks in TED patients; BLA filing expected in H2 2025. Find out how this breakthrough could reshape care.
Innovent secures NMPA approval for SYCUME, China’s first IGF-1R antibody for thyroid eye disease
Innovent Biologics has received approval from China’s National Medical Products Administration (NMPA) for SYCUME (teprotumumab N01), marking a…
Innovent Biologics NDA for IBI311 in thyroid eye disease treatment gets priority review in China
Innovent Biologics, Inc. (HKEX: 01801), a leading biopharmaceutical company, announced that its New Drug Application (NDA) for IBI311,…
Amgen seeks European approval for teprotumumab in thyroid eye disease
Amgen (NASDAQ: AMGN), a global biotechnology leader, has announced its plans to submit a Marketing Authorization Application (MAA)…